# CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)

> **NCT01195480** · PHASE1,PHASE2 · TERMINATED · sponsor: **University College, London** · enrollment: 29 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **GENETIC:** donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta
- **BIOLOGICAL:** Irradiated donor-derived Lymphoblastoid Cell Line

## Key facts

- **NCT ID:** NCT01195480
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Due to lack of biological efficacy and CD19 CAR CTL persistence
- **Last updated:** 2018-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195480, "CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01195480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*